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Summary
The coronavirus nucleocapsid (N) protein packages vi-
ral genomic RNA into a ribonucleoprotein complex. In-
teractions between N proteins and RNA are thus crucial
for the assembly of infectious virus particles. The
45 kDa recombinant nucleocapsid N protein of corona-
virus infectious bronchitis virus (IBV) is highly sensi-
tive to proteolysis. We obtained a stable fragment of
14.7 kDa spanning its N-terminal residues 29–160
(IBV-N29-160). Like the N-terminal RNA binding do-
main (SARS-N45-181) of the severe acute respiratory
syndrome virus (SARS-CoV) N protein, the crystal
structure of the IBV-N29-160 fragment at 1.85 A˚ resolu-
tion reveals a protein core composed of a five-stranded
antiparallel b sheet with a positively charged b hairpin
extension and a hydrophobic platform that are proba-
bly involved in RNA binding. Crosslinking studies
demonstrate the formation of dimers, tetramers, and
higher multimers of IBV-N. A model for coronavirus
shell formation is proposed in which dimerization of
the C-terminal domain of IBV-N leads to oligomeriza-
tion of the IBV-nucleocapsid protein and viral RNA con-
densation.
Introduction
Coronaviruses are large enveloped single-stranded
RNA viruses of positive polarity which cause a wide
spectrum of diseases affecting humans and animals (re-
viewed in Lai and Holmes, 2001). In 2003, the causative
agent for the outbreak of atypical pneumonia with a high
fatality rate was identified as the severe acute respira-
tory syndrome (SARS) coronavirus (SARS-CoV) (Peiris
et al., 2003), and its genome was rapidly sequenced
and characterized (Marra et al., 2003; Rota et al., 2003).
The potential risks for public health posed by SARS-
CoV and the current lack of specific antiviral agents or
vaccines against this emerging pathogen have triggered
a global research effort in order to characterize this fam-
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4 These authors contributed equally to this work.ily of viruses at the molecular level. Coronavirus infec-
tious bronchitis virus (IBV) causes an acute and conta-
gious disease in chickens, with a significant impact on
the poultry industry worldwide.
In structural terms, coronavirus virions are roughly
spherical, with an approximate diameter of 120 nm.
Their detailed in vivo morphology is still a matter of de-
bate but might be composed of three structural layers:
a lipid envelope with three or four glycoproteins, a pro-
tein core, and a tubular or helicoidal nucleocapsid, as
shown for the porcine transmissible gastroenteritis virus
(TGEV) (Escors et al., 2001). Low-resolution electron mi-
crographs have highlighted the crown-like structure that
surrounds the coronavirus envelope (Sturman et al.,
1980). These spikes contain the S protein, a class I fu-
sion glycoprotein (Bosch et al., 2004; Lescar et al.,
2001) which is also responsible for binding to the recep-
tor (Lai and Holmes, 2001). Two integral membrane pro-
teins, M (about 230 amino acids) and E (about 100 amino
acids), are essential for the maturation of newly formed
virions, and are sufficient for the formation of a closed
viral particle (Vennema et al., 1996). The M protein is
thought to possess three transmembrane segments
and a large C-terminal endodomain that interacts with
the nucleocapsid and possibly also with the RNA ge-
nome (Sturman et al., 1980; Kou and Masters, 2002; Nar-
ayanan et al., 2003). The nucleocapsid protein of IBV
(IBV-N) is a phosphoprotein of 409 amino acids that is
well-conserved across various IBV strains (Williams
et al., 1992) and is also important for cell-mediated im-
munity. It forms a protective shell that packages the viral
genomic RNA of 27.6 kb and is also thought to partici-
pate in viral RNA replication and transcription. Specific
packaging of viral genetic material is usually performed
via the recognition of a particular nucleotide sequence
by a nucleocapsid protein. Such ‘‘packaging signals’’
have been identified at the 30 end of the viral genomes
of mouse hepatitis virus (MHV) (Fosmire et al., 1992)
and bovine coronavirus (BCV) (Cologna and Hogue,
2000) and at the 50 end of the TGEV genome (Escors
et al., 2003), but not unambiguously for the IBV genome.
In elegant structural studies performed in other viral
families with RNA genomes, such as HIV (De Guzman
et al., 1998) and the MS2 bacteriophage (Valegard
et al., 1997), the packaging signals were seen to form
a stem-loop structure that is recognized by the nucle-
ocapsid protein. In the case of the IBV genome, this
special RNA structure has not been determined with
certainty, although previous studies demonstrated that
the IBV-N protein interacts specifically with RNA se-
quences located at the 30 noncoding region of the viral
genome (Zhou et al., 1996). Both the N- and C-terminal
domains of IBV-N, but not its middle region, bind to an
oligoribonucleotide of 155 nucleotides, located at the
30 end of the viral genome nontranslated region, but little
is known about the details of this interaction and how it
relates to virus assembly (Zhou and Collisson, 2000).
In an attempt to define how the viral genome is incor-
porated into newly formed viral particles and how this
process is coupled with nucleocapsid assembly, we
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the full-length N protein from IBV expressed in bacteria.
The full-length recombinant IBV-N protein expressed in
Escherichia coli is unstable. Through cleavage by E. coli
proteases, a stable fragment of 14.7 kDa comprising its
N-terminal residues 29–160 can be obtained. We report
here the crystal structure of this N-terminal fragment re-
fined at 1.85 A˚ resolution and compare it to the N-terminal
RNA binding domain of the SARS-CoV N protein (SARS-
N45-181), which was solved recently using NMR (Huang
et al., 2004). We demonstrate the formation of multimers
of the IBV-N protein in vitro and propose that dimers and
possibly tetramers of IBV-N, which are stabilized pre-
dominantly via dimerization of their C-terminal domains,
act as elementary building blocks for RNA genome con-
densation and nucleocapsid assembly.
Results and Discussion
Identification of a Stable Proteolytic Fragment
of IBV-N
The full-length IBV-N protein comprising 409 residues
was expressed in E. coli in a soluble form and purified
as described in the Experimental Procedures. Crystalli-
zation trials with the full-length protein produced crys-
tals that grew from a precipitate after about 3 months.
Analysis of dissolved crystals using SDS-PAGE reveals
that they contain a fragment of the full-length protein
of about 14.7 kDa (Figure 1). A domain of similar size
could be obtained by incubating the IBV-N protein at
room temperature for the same period (Figure 1). Thus,
this polypeptide fragment presumably derives from
slow proteolysis of IBV-N by traces of E. coli proteases
present in the crystallization solution. In order to identify
its nature, this proteolytically stable fragment was sub-
jected to mass spectrometry, which revealed a mass
of 14,692 Da. N-terminal amino acid sequencing identi-
fied residues Ser-Ser-Gly-Asn-Ala-Ser-Trp, which are
located at positions 29–35 of the IBV-N amino acid se-
quence. Given that Ser-29 is the first amino acid of the
fragment, the closest mapping onto the sequence gives
Leu-160 as the C-terminal residue (calculated mass
14,691 Da). The IBV-N29-160 protein shares 37% amino
acid sequence identity with the N-terminal RNA binding
domain of a comparable domain from the SARS-CoV N
protein (SARS-N45-181), whose structure was reported
recently (Figure 2).
Structure Determination and Quality of the Model
Overexpression of the recombinant N-terminal IBV-N29-
160 fragment readily gave crystals diffracting beyond
2.0 A˚ (Figure 1). Attempts to solve the structure by mo-
lecular replacement using the averaged NMR structure
of a SARS-CoV nucleocapsid N-terminal domain depos-
ited in the Protein Data Bank (PDB) (Huang et al., 2004)
were unsuccessful, even though the two structures
turned out to adopt a related fold (Figure 2). The IBV-
N29-160 protein is devoid of methionine and cysteine res-
idues. Thus, in order to assist structure determination
using the multiwavelength anomalous dispersion (MAD)
method, Ile-62, Leu-104, and Val-116 were mutated to
methionine. These hydrophobic amino acid residues
have been shown to introduce little perturbation in the na-
tive protein structure when substituted by methionineresidues (Gassner and Matthews, 1999). In addition, the
presumably exposed residue Lys-85 (as suggested by
an amino acid sequence alignment with the SARS-CoV
N protein) was mutated to Cys in order to introduce a po-
tential binding site for mercury compounds. This mutated
fragment of IBV-N29-160 was used for structure determi-
nation using the MAD method with crystals containing the
selenomethionyl protein. Data collection, phasing, and
refinement statistics are summarized in Tables 1 and 2
for the selenomethionine-derivatized crystal (SeMet) and
for the native protein crystal. Overall, the path of the
main chain is unambiguously defined in clear electron
density for the two IBV-N29-160 molecules present in
the asymmetric unit in each crystal form. A total of 134
protein residues per molecule (two extra residues at
the N terminus derive from the cloning procedure)
were included in the final models, which have excellent
stereochemical parameters as well as 182 and 188 well-
defined water molecules, respectively (Table 2). Electron
density is absent for the Lys-81 side chain which is ex-
posed to the solvent.
Overall Structure
The two monomers present in the asymmetric unit can
be superimposed with a root mean square (rms) devia-
tion of 0.5 A˚ for their main chain atoms. The IBV-N29-
160 monomer has approximate overall dimensions of
35 A˚ 3 35 A˚ 3 30 A˚ and consists of a core formed by
a five-stranded antiparallel b sheet with the topology
b4-b2-b3-b1-b5, which faces a smaller antiparallel sheet
composed of only two strands, b10-b40, which are absent
in the SARS-N protein (Figure 2). A long flexible hairpin
loop b20-b30, which is inserted between the b2 and b3
strands, protrudes largely from the protein core. This
Figure 1. Structural Domains of the IBV-N Protein
(A) Schematic representation of the IBV-N protein depicting its var-
ious domains and clustering of positive charges, as inferred from the
present and other studies.
(B) SDS-PAGE analysis of the full-length recombinant IBV-N protein
of 44.9 kDa (lane 1, arrow) and the N-terminal proteolytically stable
fragment of 14.7 kDa spanning residues 29–160 of the sequence
which was crystallized (lane 2). The recombinant IBV-N29-160 is
shown in lane 3.
(C) Typical plate-shaped crystals of the recombinant IBV-N29-160
protein.
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(A and B) Comparison of the folds adopted by IBV-N29-160 ([A]; shown as a stereoview, top) and the N-terminal domain of the SARS-CoV nu-
cleocapsid protein (B) (Huang et al., 2004). The two proteins are displayed in the same orientation. Secondary structure elements and some res-
idue numbers are indicated.
(C) Topology diagram of the IBV-N29-160 protein. Its N- and C-terminal ends are labeled.extension is mobile, as shown by higher than average
temperature factors, and contains several basic resi-
dues which are conserved across various coronavirus
N protein sequences (Figure 3). Extended loops span-
ning up to 30 residues connect the various secondary
structure elements, presumably introducing flexibility
to the overall architecture. This potential adaptability
to various structural contexts might be important for as-
sembly and disassembly of the nucleocapsid during the
virus life cycle. The overall fold is similar to the SARS-
N45-181 protein (Figure 2) with a few structural differen-
ces, such as the presence of a short 310 helix connecting
strands b10 and b2. Overall, a three-dimensional struc-
tural alignment between the SARS-CoV and IBV nucleo-
capsid N-terminal domains using the program DALI
(Holm and Sander, 1993) shows that a total of 124 equiv-
alent Ca atoms can be superimposed, with an rms devi-
ation of 3.0 A˚. The Z score is 10.4, confirming the global
similarity of the two folds. The rather large difference be-
tween the SARS-CoV and IBV nucleocapsid N-terminal
domain structures accounts for the failure of molecular
replacement procedures to solve the latter structure us-
ing the former as a model. The important structural dif-
ferences we observe between the SARS-CoV and IBV
nucleocapsid N-terminal domain structures may stem
from an inherent mobility of the coronavirus nucleocap-
sid structure or from a large uncertainty of the atomicpositions determined by NMR, or both. A search through
the PDB did not return any other protein with a statisti-
cally significant Z score, emphasizing the uniqueness
of this fold as noted by Huang et al. (2004).
Dimer Formation
In our crystal structure, the two monomers assemble
into a butterfly-shaped dimer related by a 180º rotation,
burying in this interaction an accessible surface area of
560 A˚2. The transformation is not a pure rotation, as a re-
sidual translation is needed to bring the two monomers
into coincidence. The relatively small surface area sug-
gests a rather weak binding affinity, an observation in
agreement with the fact that, using size exclusion chro-
matography, the recombinant IBV-N29-160 protein pre-
dominantly elutes as a monomer (see below). This is also
consistent with our findings of a different dimeric inter-
face adopted by the same recombinant IBV-N29-160
protein in a nonrelated crystal form (with space group
C2) that diffracts only to medium resolution.
Nucleic Acid Binding
In order to package the viral genome of 27.6 kb, the
IBV-N protein must provide extended surfaces to bind
the viral RNA genome both specifically and nonspe-
cifically (without a requirement for a special base se-
quence). N- and C-terminal regions of IBV-N
Structure
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Data Set Native SeMet
IBV-N: 29–160 IBV-N: 29–160 (Three Residues Mutated to Met)
Peak Inflection Remote
Wavelength 1.5418 0.97943 0.97956 0.98729
Cell parameters (A˚, º), P1 a = 35.48 a = 34.77
b = 35.72 b = 35.37
c = 56.11 c = 55.95
a = 99.05 a = 100.51
b = 93.93 b = 95.48
g = 109.53 g = 110.16
Resolution (A˚) 20–1.85 20–1.95
Total number of reflections 75,798 76,265 64,999 72,832
No. of unique reflection 20,031 20,083 17,032 19,684
Completeness (%)a 92.4 (88.8) 96.6 (95.0) 96.5 (95.2) 95.6 (87.8)
Multiplicityb 3.8 (3.7) 3.8 (3.7) 3.8 (3.6) 3.7 (3.5)
Rmerge
c 0.064 (0.625) 0.05 (0.118) 0.05 (0.131) 0.06 (0.177)
I/s(I) 7.4 (1.1) 8.6 (3.7) 8.3 (4.4) 9.1 (6.0)
Solvent content (%) 43.3 40.6
No. of Se sites — 6
Phasing powerd — 0.7/0.6 0.6/0.4 0.2/1.1
f 0/ f 00e — 28.1/5.7 210.5/3.3 24.3/0.5
Figure of meritf
20–2.5 A˚
— 0.61/0.793
a The numbers in parentheses refers to the last (highest) resolution shell.
b For the SeMet crystal, Friedel pairs are treated as different reflections.
c Rmerge = ShSijIhi 2 <Ih>j/Sh,i Ihi, where Ihi is the ith observation of the reflection h, while <Ih> is its mean intensity.
d Anomalous phasing power/dispersive phasing power, where anomalous phasing power is jliFhj 2 jliF2hj/anomalous lack of closure and dis-
persive phasing power is jliFhj 2 jljFhj/dispersive lack of closure.
e Values of f0 and f00 where estimated from a scan of the absorption edge using the program CHOOCH (Evans and Pettifer, 2001).
f Figures of merit are given before and after real space density modification, respectively.encompassing residues 1–171 and 268–407, respec-
tively, interact with noncoding regions of the viral geno-
mic RNA located at its 30 end (Zhou and Collisson, 2000).
Table 2. Refinement Statistics
Native SeMet
Resolution range (A˚) 19.92–1.85 20.0–1.95
Intensity cutoff (F/s(F)) none none
No. of reflections: completeness (%) 100.0 96.1
Used for refinement 18,921 16,077
Used for Rfree calculation 1,026 881
No. of nonhydrogen atoms
Protein 2130 2128
Water molecules 188 182
R factor (%)a 22.96 22.73
Rfree (%)
b 27.03 27.59
Rms deviations from ideality
Bond lengths (A˚) 0.007 0.008
Bond angles (º) 1.05 1.14
Ramachandran Plot
Residues in most favored
regions (%)
88.8 90.3
Residues in additional allowed
regions (%)
10.2 9.2
Residues in generously allowed
regions (%)
1.0 0.5
Overall G factorc 0.10 0.04
PDB accession code 2BXX 2BTL
a R factor = S kFobsj 2 jFcalck/S jFobsj.
b Rfree was calculated with 5% of reflections excluded from the
whole refinement procedure.
c G factor is the overall measure of structure quality from
PROCHECK (Laskowski et al., 1993).As the fragment 1–91 does not bind RNA, residues be-
tween 91 and 171 were proposed to either make direct
contacts with RNA or be necessary for the integrity of
the protein structure (Zhou and Collisson, 2000). Be-
cause the segment 92–95 includes strictly conserved
hydrophobic residues which are buried in the protein
core in our structure, we propose that the fragment 1–
91 studied by Zhou and Collisson (2000) was probably
poorly folded and thus nonactive. We tested nucleic
acid binding by IBV-N29-160 and found that the re-
combinant fragment was able to bind an oligoribonu-
cleotide from the 30 end of the viral genome (Figure 4).
This result is in agreement with studies by Huang et al.
(2004), who used NMR to demonstrate that SARS-CoV
N45-181 could bind a 32-mer oligoribonucleotide lo-
cated at the 30 end of the SARS-CoV genome. Interest-
ingly, this oligoribonucleotide has a highly conserved
sequence across various coronaviruses including IBV,
and adopts a unique tertiary structure (Robertson
et al., 2005). A surface representation of electrostatic
charges of the IBV-N29-160 protein shown in Figure 5 re-
veals a striking segregation in the charge distribution on
the protein surface. The b20-b30 hairpin forms a basic
patch at the thumb, whereas the base is acidic (Figure 5).
These two charged patches are separated by a neutral
and rather hydrophobic platform contributed by resi-
dues projecting from strands b4-b2-b3 that form a palm-
like structure. An alignment of nucleocapsid protein
amino acid sequences from various coronaviruses high-
lights the conservation of several residues exposed at
the protein surface, suggesting that some might play
a role in nucleic acid recognition (Figures 3 and 5). The
topology of the protein and its charge distribution
IBV Nucleocapsid Crystal Structure
1863Figure 3. Structure-Based Alignment of
Coronavirus Nucleocapsid Amino Acid Se-
quences Corresponding to the Proteolytically
Stable N-Terminal Fragment
Secondary structure elements are labeled
above the sequence for IBV-N29-160 and be-
low for the SARS-CoV N-terminal fragment
(Huang et al., 2004). Sequences of IBV (infec-
tious bronchitis virus, strain Beaudette,
NP_040838); H-CoV (human coronavirus,
strain HKU1, YP_173242); MHV (murine hepa-
titis virus, strain 1, AAA46439); TGEV (porcine
transmissible gastroenteritis virus, strain
RM4, AAG30228); and SARS (SARS-CoV,
1SSK_A) were obtained from GenBank. Con-
served residues are shaded.suggest a mode of RNA binding in which its phosphate
groups would project toward the basic b20-b30 hairpin,
possibly making electrostatic interactions with the con-
served positively charged Arg-76 and Lys-78 residues,
while the sugar and base moieties would contact the
hydrophobic platform. In this model, the exposed hy-
drophobic residues Tyr-92 and Tyr-94 (strand b3) could
form stacking interactions with the bases, as was ob-
served, for instance, in complexes between the vaccinia
virus protein VP39 and mRNA (Hu et al., 1999) or be-
tween the matrix protein VP40 from Ebola virus and a tri-
ribonucleotide (Gomis-Ruth et al., 2003). As suggested
by Huang et al. (2004), additional favorable interactions
might be formed upon closure of the flexible b20-b30 hair-
pin onto the incoming RNA ligand.
In Vitro Oligomerization of the IBV
Nucleocapsid Protein
Oligomerization of N protein has been studied in MHV
(Robbins et al., 1986) and SARS-CoV (He et al., 2004).
Trimers of N subunits linked by intermolecular disulfide
bonds were identified in MHV. Using mutational analy-
sis, the Ser/Arg-rich motif spanning residues 184–196
(immediately downstream from our crystallized frag-
ment) was shown to be essential for the multimerization
of the N protein from SARS-CoV (He et al., 2004). We an-
alyzed the oligomerization states of the full-length IBV-N
protein, IBV-N29-160, and IBV-N218-329 in solution.
Crosslinking experiments were performed using glutar-
aldehyde, a short self-polymerizing reagent mostly re-
acting with the amino and amine groups of lysine and
histidine, respectively (Buehler et al., 2005), and suberic
acid bis N-hydroxy-succinamide ester (SAB), a reagent
which only crosslinks lysine residues at larger distances.
Concentrations of crosslinking agent higher than0.1 mM led to the formation of dimers, tetramers (but
not trimers), and larger oligomers of IBV-N, along with
the disappearance of monomeric species (Figure 6).
By contrast, an approximately 20-fold higher concentra-
tion of crosslinking agent (2 mM glutaraldehyde or 1 mM
SAB; see Figure 6) was required to obtain equal amounts
Figure 4. Analysis of the RNA Binding Activity of the Full-Length
IBV-N Protein and IBV-N29-160 and IBV-N218-329 Fragments
The purified IBV-N (lanes 2 and 7), IBV-N29-160 (lanes 3 and 8), IBV-
N218-329 (lanes 4 and 9), His-tagged IBV-N29-160 (lanes 5 and 10),
and GST (negative control, lanes 6 and 11) were separated on a 15%
SDS-PAGE gel. The proteins were either visualized by Coomassie
brilliant blue staining (lanes 1–6) or transferred to Hybond C extra
membrane (Amersham) and detected by Northwestern blot with a
digoxin-labeled RNA probe corresponding to the IBV genome
sequence from nucleotides 26,539–27,608 (lanes 7–11). Molecular
masses of standard proteins are indicated.
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that regions within the C-terminal domain of IBV-N make
a predominant contribution to the multimerization of
IBV-N. Secondary structure predictions and limited pro-
teolysis studies of the IBV-N protein suggest the pres-
ence of a structured—possibly a-helical—C-terminal
domain of about 12 kDa, which is connected to IBV-
N29-160 by a Ser/Arg/Ala/Gly-rich loop of approxi-
mately 50 amino acid residues (Figure 1). We expressed
such a stable recombinant C-terminal domain encom-
passing residues 218–329 of the N protein in a soluble
form. This C-terminal domain can bind RNA (Figure 4),
fold independently, and was recently crystallized (H.F.,
D.X.L., and J.L., unpublished data). Crosslinking experi-
ments show that IBV-N218-329 forms dimers, trimers,
tetramers, and higher oligomers for concentrations of
crosslinking agent higher than 1 mM with a concomitant
decrease in monomer species, thus confirming the im-
portant contribution of the C-terminal domain of IBV to
the formation of IBV-N multimers (Figure 6). As an inde-
pendent confirmation, we subjected the IBV-N29-160
and IBV-N218-329 domains to size exclusion chro-
matography (Figure 7). Under these conditions, the
C-terminal domain IBV-N218-329 elutes faster than the
Figure 5. Proposed RNA Binding Site of IBV-N
(A) Surface representation of the IBV-N29-160 fragment with electro-
static potentials colored in blue (positive) and red (negative). Resi-
dues which are suggested to participate in RNA binding are labeled.
The N- and C-terminal ends of the polypeptide chains are indicated.
(B) Close-up view of the proposed RNA binding site of the IBV-N29-
160 fragment. The Ca trace of IBV-N29-160 is displayed. Side chains
which are likely to participate in nucleic acid binding are shown as
sticks.N-terminal domain as a sharp symmetric peak corre-
sponding to a dimer. The N-terminal domain elutes at
a position intermediate between a monomer and a dimer
(with an estimated size corresponding to a protein of mo-
lecular weight 18.1 kDa). This pattern of migration could
be due to the asymmetric shape of the IBV N-terminal
domain or could be indicative of the presence of a mix-
ture of monomer and dimer of the N-terminal domain in
solution.
Implications for Coronavirus
Nucleocapsid Assembly
Our data suggest that residues 218–329 at the
C-terminal end of the IBV-N protein play a major role
for its multimerization. This is consistent with results
reported by Surjit et al. (2004), who studied SARS-CoV
nucleocapsid dimerization using the yeast two-hybrid
system, and points to conserved assembly properties
between the SARS-CoV and IBV in spite of significant
amino acid differences between their two nucleocapsid
Figure 6. Crosslinking Experiments
(A) Full-length IBV-N protein.
(B) IBV-N29-160 protein, which was crystallized.
(C) C-terminal fragment, IBV-N218-329.
The nature and concentrations of crosslinking agent are shown.
Monomer, dimer, trimer, and tetramer species of the recombinant
proteins are indicated.
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tion by the N protein? One obvious explanation is that
multimerization increases the protein surface area ac-
cessible for binding the viral genomic RNA, thus provid-
Figure 7. Size Exclusion Chromatography Elution Profiles of IBV-
N29-160 and IBV-N218-329
The vertical axis shows absorbance at 280 nm. The horizontal axis
indicates the elution volume in milliliters. Three thin vertical lines in-
dicate the positions of molecular weight of protein standards (from
left to right: ovalbumin, 43 kDa; chymotrypsinogen A, 25.0 kDa;
and ribonuclease A, 13.7 kDa). The large difference in absorbance
stems from the different individual molar absorbance coefficients
at 280 nm of IBV-N29-160 (40,540 M21cm21) and IBV-N218-329
(4,080 M21cm21).ing the elementary building block for nucleocapsid as-
sembly. Indeed, several crystal structures of capsid
proteins have revealed the presence of multimers that
present continuous patches of basic residues at their
surface: the capsid proteins of West Nile virus and Borna
disease virus form tetrameric assemblies (Dokland et al.,
2004; Rudolph et al., 2003) and the nucleocapsid protein
of porcine respiratory syndrome virus, an arterivirus,
forms dimers (Doan and Dokland, 2003). Unfortunately,
because these structures were determined in the ab-
sence of an RNA ligand, it is difficult to evaluate to
what extent multimer formation is coupled with nucleic
acid recognition. In the Arteviridae, a viral family
genomically related to the coronaviruses, the basic
N-terminal half of the nucleocapsid protein is involved
in RNA binding while its C-terminal domain forms a tight
dimer (Doan and Dokland, 2003).
Further complexity for the study of coronavirus nucle-
ocapsid assembly stems from its interaction with the
M protein endodomain (Kou and Masters, 2002; Nar-
ayanan et al., 2000, 2003) and from the fact that several
coronavirus proteins can interact with single-stranded
RNA, including the nsp9 replicase protein from SARS-
CoV (Egloff et al., 2004; Sutton et al., 2004). In the ab-
sence of a nucleic acid ligand, the N protein appears
to be composed of two main globular domains loosely
connected by Arg/Ser/Ala/Gly-rich loops that are highly
sensitive to proteolysis. These connecting regions may
undergo modifications (e.g., phosphorylation) that could
influence the multimerization state of the protein and
control its interaction with RNA. In a recent report, su-
moylation of Lys-62 of SARS-CoV N protein expressed
in mammalian cells was proposed to promote dimeriza-
tion of the protein (Li et al., 2005). It is not known whether
similar modifications of the IBV-N occur in virus-infected
cells. Nevertheless, a working hypothesis for coronavi-
rus nucleocapsid formation can be proposed (Figure 8).
In this model, viral genomic RNA binding by both the
N- and C-terminal domains would lead to a clusteringFigure 8. Hypothetical Model for the Assem-
bly of the IBV Ribonucleoprotein Complex
(A) Both the N- (cyan) and C-terminal (green)
domains of the IBV-N protein can bind RNA
(represented as a thin orange line). The basic
patch in IBV-N29-160 is depicted by plus
signs. Dimerization of the C-terminal
domains (arrows) leads to a clustering of
IBV-N proteins and to their oligomerization.
(B) The endodomain of the integral mem-
brane protein M can provide further contacts
to the ribonucleocapsid (see text). However,
the precise coupling between RNA recogni-
tion and IBV-N multimerization remains un-
certain.
Structure
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would trigger oligomerization of the N-terminal domains
by increasing their local concentration above a certain
threshold. In turn, this would trigger condensation of
viral RNA. Interdomain flexibility we have defined in the
linker regions could facilitate the necessary conforma-
tional changes during the transition to a more compact
form of the ribonucleocapsid (Figure 8).
Further studies are underway to elucidate the three-
dimensional structure of the globular C-terminal domain
of IBV-N, to define the interactions between the IBV-N
protein and viral RNA, and to characterize the morphol-
ogy of the ribonucleocapsid.
Experimental Procedures
Cloning and Expression
The gene encoding the IBV-N protein was amplified by PCR using
the Pfu polymerase (Stratagene, Singapore) with the forward (50-AT
TATT CAT ATG GCA AGC GGT AAA GCA GC-30) and reverse primer
(50-ATTATT CTC GAG TCA AAG TTC ATT CTC TCC TA-30) and
cloned into the pET 29b vector using T4 ligase (Research Biolabs,
Singapore). The underlined sequences correspond to NdeI and
XhoI sites, respectively. Proteins (lacking the His6 tag due to the in-
sertion of a stop codon in the reverse primer) were expressed in
E. coli BL21(DE3). The cells were grown at 37ºC in Luria-Bertani me-
dium containing 100 mg/ml ampicillin until the culture reached an
OD600 of 0.7. Protein expression was induced by the addition of
1 mM isopropyl-b-D-thiogalactopyranoside for 3 hr at 30ºC. Cells
harvested and resuspended at 4ºC in a buffer containing 20 mM
Na3PO4 (pH 7.8) were lysed by sonication and the remaining insolu-
ble material was removed by centrifugation at 20,0003 g for 20 min
at 4ºC. N- and C-terminal fragments of the IBV-N gene coding for
residues 29–160 and 218–329, respectively, were cloned into pET-
16b using the following primers: 50-AATA CATATG TCT TCT GGA
AAT GCA TCT TG-30; 50-AATA CTC GAG TCA CAG GGG AAT GAA
GTC CC-30 and 50-A AATA CAT ATG AAG GCA GAT GAA ATG
GC-30; 50-AA ATA CTC GAG TCA CGT TCC TAC ACC ATC GAC-30.
These two proteins (hereafter named IBV-N29-160 and IBV-N218-
329, respectively) were expressed as described above for IBV-N,
yielding truncated fragments having a His10 tag at their N terminus
followed by a Factor Xa cleavage site. The His10 tags were cleaved
during purification. Expression of the selenomethionylated protein
IBV-N29-160 was carried out as described in Doublie´ (1997).
Analysis of the Proteolytically Stable Fragment Derived
from IBV-N
Automated N-terminal amino acid sequence determination of the
proteolytic fragment obtained by degradation of IBV-N was per-
formed using an Applied Biosystems (Singapore) Procise se-
quencer. The molecular mass of purified proteins was analyzed us-
ing a MALDI-TOF mass spectrometer (API 300 MS/MS; Applied
Biosystems).
Protein Purification
The IBV-N protein precipitated with ammonium sulfate at 30% satu-
ration, was centrifuged and resuspended in PBS, dialyzed against
buffer A (20 mM HEPES, 1 mM EDTA, 1 mM DTT [pH 6.8]), and loaded
onto a cation exchange chromatography column (Mono S HR 5/5;
GE Biosciences, Singapore) preequilibrated with buffer A. Elution
was carried out using an NaCl gradient of buffer B (20 mM HEPES,
1 mM EDTA, 1 mM DTT, 1 M NaCl [pH 6.8]). Fractions containing
the protein—as shown by SDS-PAGE—were pooled and concen-
trated to 10–15 mg/ml by ultrafiltration using a Centriprep device
(Millipore, Singapore) with a molecular weight cutoff of 10 kDa.
Size exclusion chromatography (Superdex 75; Amersham) was car-
ried out in a buffer containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl,
1 mM DTT, 0.1% NaN3. The protein was concentrated to 10 mg/ml as
determined by the Bradford assay (Bio-Rad, Singapore), using BSA
as a standard. The truncated recombinant IBV-N29-160 was resus-
pended in PBS and loaded onto an Ni-NTA column (Qiagen, Singa-
pore) preequilibrated with 20 mM KH2PO4, 50 mM NaCl (pH 7.8). Af-ter washing with 20 mM KH2PO4, 1 M NaCl, 10 mM imidazole (pH
7.2), IBV-N29-160 was eluted using a buffer containing 20 mM
KH2PO4, 0.5 M NaCl, 0.5 M imidazole (pH 6.0). The His10 tag was re-
moved by proteolysis with Factor Xa in a buffer containing 100 mM
NaCl, 2 mM CaCl2, 10 mM Tris (pH 8.0) using a substrate enzyme mo-
lar ratio of 50:1 for 4 hr at room temperature. The cleavage mixture
was loaded onto a benzamidine column to eliminate Factor Xa,
and the IBV-N29-160 protein recovered in the flow through was sub-
jected to two final steps of purification as described above for the
full-length IBV-N protein. Purification of the recombinant IBV-
N218-329 was carried out using a similar protocol. Purification of
the selenomethionine-substituted protein was performed using the
same protocol as the native protein.
Crystallization of IBV-N29-160
Crystals of the recombinant IBV-N29-160 were grown at 18ºC by va-
por diffusion using the hanging drop method. Two microliters of the
protein at a concentration of 10 mg/ml was mixed with an equal vol-
ume of the precipitating solution from the well (0.1 M sodium sulfate,
20% PEG 3350), yielding plate-shaped crystals growing to maxi-
mum dimensions of about 0.3 3 0.3 3 0.05 mm3 in about 2 weeks
(Figure 1). Crystals of the selenomethionine protein were obtained
under the same conditions.
Data Collection, Structure Determination, and Refinement
For data collection, crystals were soaked in a cryoprotecting solu-
tion (25% glycerol, 0.1 M sodium sulfate, 20% PEG 3350 [pH 6.5]) be-
fore being mounted and cooled to 100 K in a nitrogen gas stream
(Oxford Cryosystems, Oxford, UK). Diffraction intensities at three
wavelengths (Table 1) were recorded from a selenomethionine
(SeMet)-derivatized IBV-N29-160 crystal on beamline NW12 at the
Photon Factory (Tsukuba, Japan) on an ADSC charge-coupled de-
vice (CCD) detector (ADSC Corporation, Poway, CA) using an atten-
uated beam of dimensions 0.13 0.1 mm2 (Table 1). Integration, scal-
ing, and merging of the intensities were carried out using programs
from the CCP4 (1994). The six selenium atoms present within the two
molecules of the asymmetric unit were located using the program
SOLVE (Terwilliger, 2003). An initial electron density map was calcu-
lated and modified using the program RESOLVE (Terwilliger, 2003),
using these selenium atom positions to locate the noncrystallo-
graphic symmetry (ncs) axis relating the two molecules in the asym-
metric unit, and model building was first carried out in this map using
the program O (Jones et al., 1991). For subsequent cycles, electron
density maps were calculated using partial model phases combined
with experimental MAD phases with the program REFMAC5 from the
CCP4 (1994), which was used for the initial refinement of the struc-
ture, that included ncs restraints. A few cycles of refinement using
molecular dynamics with a slow cooling protocol using a maximum
likelihood target incorporating phase probability distribution en-
coded in the form of Hendrickson Lattman coefficients were subse-
quently carried out using the program CNS (Brunger et al., 1998),
with ncs restraints. A data set for the native protein was collected
on an R axis IV++ image plate detector using CuKa radiation from
a Micromax-007 rotating anode (Rigaku/MSC, The Woodlands, TX)
operating at 20 mA and 40 kV (Table 1). The SeMet model was placed
in the native crystal form and adjustments to the model were carried
out using difference Fourier maps calculated with REFMAC5, which
was used for refinement. Superposition of structures and rms devi-
ation calculations were carried out using the program LSQKAB from
the CCP4 (1994). Figures 2 and 5 were produced with the program
PyMOL (DeLano, 2002).
Crosslinking Experiments
The purified recombinant proteins IBV-N, IBV-N29-160, and IBV-
N218-329 were incubated with either glutaraldehyde or SAB
(Sigma-Aldrich, St. Louis, MO) for 2 hr at 20ºC using a constant
amount of protein (5 mg) with increasing amounts of the crosslinking
agent. The samples were submitted to electrophoresis on an 8%–
15% SDS-PAGE gel and stained with Coomassie blue.
Size Exclusion Chromatography
A Superdex 75 10/300 GL size exclusion chromatographic column
(Amersham) mounted on an AKTA FPLC (GE Biosciences, Singa-
pore) was used to analyze the homogeneity and apparent
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1867multimerization states of IBV-N29-160 and IBV-N218-329, respec-
tively. Protein concentrations used were 10 mg/ml and the loaded
sample volume was 0.1 ml. The buffer was 10 mM Tris-HCl, 0.2 M
NaCl, 3 mM b-mercapto-ethanol (pH 7.5) and the flow rate was 0.5
ml/min. Standard protein markers (Amersham) used for calibration
were ribonuclease A, 13.7 kDa, elution 14.88 ml; chymotrypsinogen
A, 25.0 kDa, 13.81 ml; ovalbumin, 43.0 kDa, 11.81 ml; BSA, 67.0 kDa,
10.89 ml. Apparent size/molecular weights were deduced by plot-
ting Kav versus log (MW) with Kav = (Ve 2 V0)/(Vt 2 V0), where Ve is
the elution volume of the protein, Vt is the total column bed volume,
and V0 is the void volume.
RNA Binding Assay
The full-length IBV-N protein and the IBV-N29-160 and IBV-N218-
329 fragments were expressed in E. coli BL21 cells and purified as
described above. The polyhistidine tags of the truncated proteins
were removed by digestion with Factor Xa. The purified proteins
were separated on 15% SDS-PAGE, transferred to Hybond C extra
membrane (Amersham), and probed with digoxin-labeled RNA rep-
resenting the negative sense of the IBV genome from nucleotides
25,873–27,608. The probe was made by in vitro transcription using
SP6 polymerase in the presence of digoxin according to the manu-
facturer’s instructions (Roche, Singapore).
Acknowledgments
We thank Jacques d’Alayer (Institut Pasteur) for performing N-termi-
nal amino acid sequencing, and Terje Dokland and Soichi Wakatsuki
for help and very useful discussions. Financial support via grants
from NTU (SUG 14/02), the Singapore Biomedical Research Council
(03/1/21/20/291 and 02/1/22/17/043), and the Singapore National
Medical Research Council (NMRC/SRG/001/2003) to the Lescar lab-
oratory is acknowledged as well as provision of excellent beam time
by the Photon Factory (Japan).
Received: May 30, 2005
Revised: August 9, 2005
Accepted: August 30, 2005
Published: December 13, 2005
References
Bosch, B.J., Martina, B.E., Van Der Zee, R., Lepault, J., Haijema,
B.J., Versluis, C., Heck, A.J., De Groot, R., Osterhaus, A.D., and Rot-
tier, P.J. (2004). Severe acute respiratory syndrome coronavirus
(SARS-CoV) infection inhibition using spike protein heptad repeat-
derived peptides. Proc. Natl. Acad. Sci. USA 101, 8455–8460.
Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P.,
Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M.,
Pannu, N.S., et al. (1998). Crystallography & NMR system: a new
software suite for macromolecular structure determination. Acta
Crystallogr. D Biol. Crystallogr. 54, 905–921.
Buehler, P.W., Boykins, R.A., Jia, Y., Norris, S., Freedberg, D.I., and
Alayash, A.I. (2005). Structural and functional characterization of glu-
taraldehyde polymerized bovine hemoglobin and its isolated frac-
tions. Anal. Chem. 77, 3466–3478.
CCP4 (Collaborative Computational Project, Number 4) (1994). The
CCP4 suite: programs for protein crystallography. Acta Crystallogr.
D Biol Crystallogr. 50, 760–763.
Cologna, R., and Hogue, B.G. (2000). Identification of a bovine coro-
navirus packaging signal. J. Virol. 74, 580–583.
De Guzman, R.N., Wu, Z.R., Stalling, C.C., Pappalardo, L., Borer,
P.N., and Summers, M.F. (1998). Structure of the HIV-1 nucleocapsid
protein bound to the SL3 c-RNA recognition element. Science 279,
384–388.
DeLano, W.L. (2002). The PyMOL User’s Manual (San Carlos, CA:
DeLano Scientific).
Doan, D.N.P., and Dokland, T. (2003). Structure of the nucleocapsid
protein of porcine reproductive and respiratory syndrome virus.
Structure 11, 1445–1451.Dokland, T., Walsh, M., Mackenzie, J.M., Khromykh, A.A., Ee, K.H.,
and Wang, S. (2004). West Nile virus core protein; tetramer structure
and ribbon formation. Structure 12, 1157–1163.
Doublie´, S. (1997). Preparation of selenomethionyl proteins for
phase determination. Methods Enzymol. 276, 523–530.
Egloff, M.-P., Ferron, F., Campanacci, V., Longhi, S., Rancurel, C.,
Dutartre, H., Snijder, E.J., Gorbalenya, A.E., Cambillau, C., and Ca-
nard, B. (2004). The severe acute respiratory syndrome coronavirus
replicative protein nsp9 is a single stranded RNA-binding subunit
unique in the RNA virus world. Proc. Natl. Acad. Sci. USA 101,
3792–3796.
Escors, D., Ortego, J., Laude, H., and Enjuanes, L. (2001). The mem-
brane M protein carboxy terminus binds to transmissible gastro-
enteritis coronavirus core and contributes to core stability. J. Virol.
75, 1312–1324.
Escors, D., Izeta, A., Capiscol, C., and Enjuanes, L. (2003). Transmis-
sible gastroenteritis coronavirus packaging signal is located at the 50
end of the virus genome. J. Virol. 77, 7890–7902.
Evans, G., and Pettifer, R.F. (2001). CHOOCH: a program for deriving
anomalous-scattering factors from X-ray fluorescence spectra.
J. Appl. Crystallogr. 34, 82–86.
Fosmire, J.A., Hwang, K., and Makino, S. (1992). Identification and
characterization of a coronavirus packaging signal. J. Virol. 66,
3522–3530.
Gassner, N.C., and Matthews, B.W. (1999). Use of differentially
substituted selenomethionine proteins in X-ray structure determina-
tion. Acta Crystallogr. D Biol. Crystallogr. 55, 1967–1970.
Gomis-Ruth, F.X., Dessen, A., Timmins, J., Bracher, A., Kolesni-
kowa, L., Becker, S., Klenk, H.D., and Weissenhorn, W. (2003). The
matrix protein VP40 from Ebola virus octamerizes into pore-like
structures with specific RNA binding properties. Structure 11, 423–
433.
He, R., Dobie, F., Ballantine, M., Leeson, A., Li, Y., Bastien, N., Cutts,
T., Andonov, A., Cao, J., Booth, T.F., et al. (2004). Analysis of multi-
merization of the SARS coronavirus nucleocapsid protein. Biochem.
Biophys. Res. Commun. 316, 476–483.
Holm, L., and Sander, C. (1993). Protein structure comparison by
alignment of distance matrices. J. Mol. Biol. 233, 123–138.
Hu, G., Gershon, P.D., Hodel, A.E., and Quiocho, F.A. (1999). mRNA
cap recognition: dominant role of enhanced stacking interactions
between methylated bases and protein aromatic side chains.
Proc. Natl. Acad. Sci. USA 96, 7149–7154.
Huang, Q., Yu, L., Petros, A.M., Gunasekera, A., Liu, Z., Xu, N., Haj-
duk, P., Mack, J., Fesik, S.W., and Olejniczak, E.T. (2004). Structure
of the N-terminal RNA-binding domain of the SARS CoV nucleocap-
sid protein. Biochemistry 43, 6059–6063.
Jones, T.A., Zhou, J.-Y., Cowan, S.W., and Kjeldgaard, M. (1991). Im-
proved methods for the building of protein models in electron den-
sity and the location of errors in these models. Acta Crystallogr. A
47, 110–119.
Kou, L., and Masters, P.S. (2002). Genetic evidence for a structural
interaction between the carboxy termini of the membrane and nucle-
ocapsid proteins of mouse hepatitis virus. J. Virol. 76, 4987–4999.
Lai, M.M.C., and Holmes, K.V. (2001). Coronaviridae: The Viruses
and Their Replication in Fundamental Virology, 4th Edition (Philadel-
phia: Lippincott Raven).
Laskowski, R.A., MacArthur, M.W., Moss, D.S., and Thornton, J.M.
(1993). PROCHECK: a program to check the stereochemical quality
of protein structures. J. Appl. Crystallogr. 26, 283–291.
Lescar, J., Roussel, A., Wien, M.W., Navaza, J., Fuller, S.D., Wengler,
G., Wengler, G., and Rey, F.A. (2001). The fusion glycoprotein shell of
Semliki Forest virus: an icosahedral assembly primed for fusogenic
activation at endosomal pH. Cell 105, 137–148.
Li, F.Q., Xiao, H., Tam, J.P., and Liu, D.X. (2005). Sumoylation of the
nucleocapsid protein of severe acute respiratory syndrome associ-
ated coronavirus. FEBS Lett. 579, 2387–2396.
Marra, M.A., Jones, S.J., Astell, C.R., Holt, R.A., Brooks-Wilson, A.,
Butterfield, Y.S., Khattra, J., Asano, J.K., Barber, S.A., Chan, S.Y.,
et al. (2003). The genome sequence of SARS-associated coronavi-
rus. Science 300, 1399–1403.
Structure
1868Narayanan, K., Maeda, A., Maeda, J., and Makino, S. (2000). Charac-
terization of the coronavirus M protein and nucleocapsid in infected
cells. J. Virol. 74, 8127–8134.
Narayanan, K., Chen, C.J., Maeda, J., and Makino, S. (2003). Nucle-
ocapsid-independent specific viral RNA packing via viral envelope
protein and viral RNA signal. J. Virol. 77, 2922–2927.
Peiris, J.S., Chu, C.M., Cheng, V.C., Chan, K.S., Hung, I.F., Poon,
L.L., Law, K.I., Tang, B.S., Hon, T.Y., Chan, C.S., et al. (2003). Clinical
progression and viral load in a community outbreak of coronavirus
associated SARS pneumonia: a prospective study. Lancet 361,
1767–1772.
Robbins, S.G., Frana, M.F., McGowan, J.J., Boyle, J.F., and Holmes,
K.V. (1986). RNA-binding proteins of coronavirus MHV: detection of
monomeric and multimeric N protein with an RNA overlay-protein
blot assay. Virology 150, 402–410.
Robertson, M.P., Igel, H., Baertsch, R., Haussler, D., Ares, M., Jr.,
and Scott, W.G. (2005). The structure of a rigorously conserved
RNA element within the SARS virus genome. PLoS Biol. 3, e5.
Rota, P.A., Oberste, M.S., Monroe, S.S., Nix, W.A., Campagnoli, R.,
Icenogle, J.P., Pen˜aranda, S., Bankamp, B., Maher, K., Chen, M.-h.,
et al. (2003). Characterization of a novel coronavirus associated with
severe acute respiratory syndrome. Science 300, 1394–1398.
Rudolph, M.G., Kraus, I., Dickmanns, A., Eickmann, M., Garten, W.,
and Ficner, R. (2003). Crystal structure of the borna disease virus nu-
cleoprotein. Structure 11, 1219–1226.
Sturman, L.S., Holmes, K.V., and Behnke, J. (1980). Isolation of co-
ronavirus envelope glycoproteins and interaction with the viral nu-
cleocapsid. J. Virol. 33, 449–462.
Surjit, M., Liu, B., Kumar, P., Chow, V.T.K., and Lal, S.K. (2004). The
nucleocapsid protein of the SARS coronavirus is capable of self as-
sociation through a C-terminal 209 amino acid interaction domain.
Biochem. Biophys. Res. Commun. 317, 1030–1036.
Sutton, G., Fry, E., Carter, L., Sainsbury, S., Walter, T., Nettleship, J.,
Berrow, N., Owens, R., Gilbert, R., Davidson, A., et al. (2004). The
nsp9 replicase protein of SARS-coronavirus, structure and func-
tional insights. Structure 12, 341–353.
Terwilliger, T.C. (2003). SOLVE and RESOLVE: automated structure
solution and density modification. Methods Enzymol. 374, 22–37.
Valegard, K., Murray, J.B., Stonehouse, N.J., van den Worm, S.,
Stockley, P.G., and Liljas, L. (1997). The three-dimensional struc-
tures of two complexes between recombinant MS2 capsids and
RNA operator fragments reveal sequence-specific protein-RNA in-
teractions. J. Mol. Biol. 270, 724–738.
Vennema, H., Godeke, G.J., Rossen, J.W.A., Voorhout, W.F., Horzi-
nek, M.C., Opstelten, D.J., and Rottier, P.J.M. (1996). Nucleocapsid-
independent assembly of coronavirus-like particles by co-expres-
sion of viral envelope protein gene. EMBO J. 15, 2020–2029.
Williams, A.K., Wang, L., Sneed, L.W., and Collisson, E.W. (1992).
Comparative analysis of the nucleocapsid genes of several strains
of infectious bronchitis virus and other coronaviruses. Virus Res.
25, 213–222.
Zhou, M., and Collisson, E.W. (2000). The amino and carboxyl do-
mains of the infectious bronchitis virus nucleocapsid protein interact
with 30 genomic RNA. Virus Res. 67, 31–39.
Zhou, M., Williams, A.K., Chung, S.I., Wang, L., and Collisson, E.W.
(1996). The infectious bronchitis virus nucleocapsid protein binds
RNA sequences in the 30 terminus of the genome. Virology 217,
191–199.
